By George Ongkojoyo 
The landscape of oncology is undergoing a fundamental shift as researchers move beyond examining tumors in isolation to understanding the systemic environment of the patient’s body. A landmark study led by researchers at University College London (UCL) and the Francis Crick Institute has revealed that the immune systems of cancer patients are profoundly disrupted, but more importantly, that the concentration of immune cells in a patient’s blood serves as a powerful predictor of long-term survival. Using a groundbreaking computational tool named ImmuneLENS (Immune Lymphocyte Estimation from Nucleotide Sequencing), scientists have demonstrated that patients with higher proportions of circulating T cells experience a 47% lower risk of death over a five-year period following surgery.
This research, published in the journal Nature Genetics, represents a significant leap forward in genomic medicine. By utilizing Whole Genome Sequencing (WGS) data—a resource traditionally used to identify genetic mutations within tumors—the team has found a way to "interrogate" the blood’s immune profile without the need for additional, costly diagnostic tests. The study suggests that the systemic immune state may be a more accurate indicator of a patient’s prognosis than the number of immune cells found within the tumor itself, a finding that could revolutionize how clinicians approach treatment plans and personalized medicine.
The Mechanics of ImmuneLENS and Whole Genome Sequencing
At the heart of this discovery is ImmuneLENS, a pioneering analytical tool designed to extract new layers of information from existing genetic data. Whole Genome Sequencing is an exhaustive process that maps the entirety of an individual’s DNA. In a clinical setting, WGS is often performed using a blood sample to provide a reference point for the patient’s "normal" genetic makeup, which is then compared against the mutated DNA of their tumor.
Historically, the information regarding immune cells within these blood-based WGS samples was treated as "noise" or simply overlooked in favor of identifying specific oncogenic mutations. ImmuneLENS changes this paradigm by looking at the "haystack" of genetic data to identify the specific signatures of T cells and B cells. T cells are the primary "soldiers" of the immune system, responsible for identifying and destroying infected or cancerous cells, while B cells produce antibodies to neutralize threats.
Dr. Robert Bentham, the study’s first author from the UCL Cancer Institute, described the innovation as a shift in perspective. "Lots of approaches that measure immune cells from genetic data are like looking for a needle in a haystack," Bentham explained. "Our approach in this study instead looks at the haystack itself and asks how the presence of immune cells changes its overall shape. It’s a different, more efficient way of finding the needle."
A Data-Driven Breakthrough: The 100,000 Genomes Project
The scale of this study was made possible through the 100,000 Genomes Project, a monumental UK government initiative managed by Genomics England in partnership with NHS England. Launched with the goal of sequencing the genomes of NHS patients with rare diseases and common cancers, the project provided a massive repository of data for the UCL team.
The researchers analyzed over 90,000 WGS samples, comparing the immune profiles of healthy individuals with those of cancer patients. This vast dataset allowed the team to observe trends that would be invisible in smaller clinical trials. One of the most striking observations was that cancer patients, across the board, exhibited a significantly lower proportion of T cells in their blood compared to healthy counterparts. This suggests that cancer does not just exist as a localized growth but acts as a systemic disease that suppresses or exhausts the body’s primary defense mechanisms.
The Predictive Power of Systemic Immunity
The most critical finding of the study centers on the correlation between T cell levels and patient outcomes. The researchers found that the proportion of T cells in the blood was a "strong predictor" of cancer outcomes. Specifically, patients who maintained a higher level of circulating T cells had a 47% higher survival rate five years after surgical intervention.
Remarkably, this association remained statistically significant even after the researchers adjusted for variables such as the patient’s age, the stage of the cancer, and the specific type of malignancy. This suggests that the systemic immune "fitness" of a patient is a universal factor in survival, transcending the traditional boundaries of cancer classification.
Professor Nicholas McGranahan, the study’s senior author from the UCL Cancer Institute, noted the significance of looking outside the tumor. "Most immune system analysis until now has focused on the tumour itself," McGranahan said. "What’s going on with immune cells in the blood seems to have a huge impact on cancer survival and may be able to predict how long a cancer patient will survive better than the number of T cells in the tumour alone."
Chronology of Development and Genomic Context
The development of ImmuneLENS is the latest milestone in a decade-long journey toward integrating genomics into standard cancer care.
- 2012: The UK government announces the 100,000 Genomes Project, aiming to bring the benefits of precision medicine to the NHS.
- 2018: The project reaches its goal of sequencing 100,000 genomes, creating one of the world’s largest databases of genetic information.
- 2021: Researchers develop an earlier iteration of the current tool, which was capable of calculating T cell proportions but was limited to Whole Exome Sequencing (WES) data, which covers only a small fraction of the genome.
- 2023-2024: The development of ImmuneLENS allows for the analysis of the much more comprehensive Whole Genome Sequencing data, leading to the current findings published in Nature Genetics.
- Future: The team has recently secured a Cancer Research UK (CRUK) Biomarker Project Award to begin the process of translating these findings into a clinical tool for NHS doctors.
Gender Differences and the "Immune Aging" Phenomenon
The study also shed light on how age and gender influence the immune system’s ability to fight cancer. It is a known biological fact that the immune system weakens with age—a process known as immunosenescence. However, the UCL study found that this decline happens much more rapidly in individuals with cancer.
Furthermore, the data revealed a distinct gender disparity. The reduction in immune cell proportions was more pronounced in male cancer patients than in female patients. While the exact reason for this difference remains unclear, it provides a new avenue for investigating why certain cancers may progress differently in men and women and could lead to more gender-specific treatment strategies in the future.
B Cells: The "Early Warning System" for Cancer
While T cells were the primary focus for survival prediction, the study’s findings regarding B cells were equally provocative. B cells are responsible for producing antibodies, and ImmuneLENS allowed the researchers to distinguish between different types of B cells for the first time using WGS data.
The team observed that individuals who appeared healthy at the time of their DNA sequencing but later developed cancer often had below-average levels of B cells in their blood. This suggests that the immune system may undergo subtle changes months or even years before a clinical diagnosis of cancer is made. These pre-cancerous shifts could potentially serve as a biological "early warning system," allowing for earlier detection when the disease is most treatable.
Additionally, the study highlighted the importance of a specific subset of B cells—those producing IgM/D antibodies. These are the antibodies produced when the body first encounters a foreign threat. The research showed that these specific B cells were the only type associated with improved survival, suggesting they play a unique and vital role in recognizing and attacking new tumor cells.
Clinical Implications and the Future of Immunotherapy
The practical applications of this research are substantial. Because the data used by ImmuneLENS is already being collected as part of standard genetic diagnostic tests in many healthcare systems, the tool could be implemented at virtually no extra cost to the taxpayer or the patient.
"Knowing whether a patient has relatively high or low numbers of immune cells in the blood… could help clinicians to decide on the best course of treatment for the individual," Professor McGranahan emphasized. For example, patients with low systemic immune counts might require more aggressive intervention or different types of immunotherapy, while those with high counts might have a better prognosis and could be spared from overly toxic treatments.
This is particularly relevant for immunotherapy, a class of drugs that works by "unleashing" the immune system to attack cancer. Currently, doctors often look for biomarkers within the tumor to see if a patient will respond to these drugs. However, if the systemic immune system is already exhausted, the drugs may be less effective. ImmuneLENS provides a way to gauge the "reserve" of the immune system, offering a more holistic view of the patient’s capacity to respond to therapy.
Official Responses and Strategic Vision
The research has been met with enthusiasm from the broader scientific community. Dr. Nisharnthi Duggan, Research Information Manager at Cancer Research UK, hailed the study as a product of a "golden age of research."
"Cancer Research UK is pleased to support this ongoing work investigating whether measuring immune cell levels in our blood can help predict cancer survival," Duggan stated. "Further research is needed, but this could one day become a tool to help doctors personalise treatment for people with cancer."
The study is part of the larger TRACERx project (TRAcking Cancer Evolution through therapy/Rx), a multi-million-pound initiative aimed at understanding how cancer cells evolve and why they become resistant to treatment. By integrating systemic immune data into the TRACERx framework, researchers hope to build a comprehensive map of the "arms race" between the human immune system and evolving cancer cells.
As the team moves toward clinical translation, the goal remains clear: to turn complex genetic data into actionable insights that can save lives. The ability to monitor the body’s internal defenses through a simple blood-based genetic record marks a new era in the fight against cancer—one where the patient’s own biology is the most important guide for their recovery.
